Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
NAFLD, Obesity
Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)
Epidemiological data and studies in animal models suggest, that polyunsatured fatty acids (PUFA) rather than mono-unsatured fatty acids (MUFA) are associated with lower hepatic lipid content (HCL) and may facilitate a decrease of…
- Conditions
- NAFLD, Obesity, Prediabetes, Dyslipoproteinemia
- Trial name
- UFOP-2 (NCT02458586)
- Testing
- Dietary intervention / counseling
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- German Institute of Human Nutrition
MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Trial name
- NCT06735924
- Testing
- Low-oxalate fixed diet
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Nonalcoholic Steatohepatitis
Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis
This study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of Rosuvastatin versus Coenzyme Q10 on nonalcoholic steatohepatitis patients.
- Trial name
- NCT05731596
- Testing
- Rosuvastatin 20 Mg Oral Tablet, Coenzyme Q10 100 MG Oral Capsule
- Volunteers
- 46 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
Aronia and Non-alcoholic Fatty Liver Disease
Adults newly diagnosed with NAFLD will be included in the study. At the beginning of the research, the socio-demographic characteristics and nutritional habits of the individuals will be questioned with a face-to-face…
- Trial name
- NCT06450769
- Testing
- Aronia juice, Mediterranean diet, Low-fat diet
- Volunteers
- 54 people
- Sponsor
- Istanbul Kent University
NASH - Nonalcoholic Steatohepatitis
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a minimally-invasive test of liver function and physiology which has been designated by the FDA as an investigational drug/device combination…
- Trial name
- NCT03294941
- Testing
- HepQuant SHUNT Liver Diagnostic Kit
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- HepQuant, LLC
NASH - Nonalcoholic Steatohepatitis
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks.
- Trial name
- NCT04697810
- Testing
- Namodenoson
- Where
- 24 sites in Bosnia and Herzegovina, Bulgaria and 4 more
- Volunteers
- 114 people
- Sponsor
- Can-Fite BioPharma
Obesity
Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.
It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients within this group have a more serious liver…
- Trial name
- NCT00280527
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Northwestern University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD
1. To evaluate hepatic fibrosis and steatosis using MR imaging, transient elastography (TE), and serum biomarker 2. To develop non-invasive diagnosis marker for NASH and advanced fibrosis
- Trial name
- NCT03725631
- Testing
- Imaging and serologic evaluation of fibrosis and steatosis
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Korea University Guro Hospital
Nonalcoholic Steatohepatitis
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on…
- Trial name
- CONTROL (NCT02633956)
- Testing
- Obeticholic Acid, Atorvastatin
- Where
- 22 sites in United States
- Volunteers
- 84 people
- Sponsor
- Intercept Pharmaceuticals
Fatty Liver
Weight Management in Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is one of the most common chronic liver diseases. The cause of NASH is not completely understood and currently there is no effective treatment for this disease.
- Trial name
- NCT00266019
- Testing
- Weight Management (diet, exercise, and behavior modification)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of…
- Trial name
- NCT04594954
- Testing
- Diet, FMT, Physical Activity
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Nonalcoholic Steatohepatitis
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
A Randomized, Controlled, Double-blind, Parallel Group, Single Center Phase 2 Clinical Trial to Evaluate Multiple Non-Invasive Liver Fibrosis Imaging Methods in the Assessment of the Efficacy of GR-MD-02 for the Treatment of…
- Trial name
- NASH-FX (NCT02421094)
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Galectin Therapeutics Inc.
Fatty Liver Disease, Chronic Glomerular Disease
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
The association of metabolic associated fatty liver disease in patients with chronic glomerular disease
- Trial name
- NCT06691529
- Volunteers
- 500 people
- Sponsor
- Assiut University
Covid19, NAFLD
COVID-19 and Nonalcoholic Fatty Liver Disease
COVID-19 is currently the leading public health problem, associated with a high risk of complications and death in risk groups of patients.
- Trial name
- CovidFAT (NCT04982328)
- Testing
- Th17 cytokine profile, Screening for the components of metabolic syndrome, Evaluation of the degree of steatosis
- Where
- Croatia
- Volunteers
- 120 people
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Non-alcoholic Steatohepatitis
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
- Trial name
- NCT02912260
- Testing
- MGL-3196
- Where
- 26 sites in United States
- Volunteers
- 125 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Obesity, Morbid, Obesity
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction
A recent review demonstrated that Non-alcoholic fatty liver disease (NAFLD) affects 10-35% of the adult population worldwide, with the prevalence approaching 85-100% in obese populations.
- Conditions
- Obesity, Morbid, Obesity, NAFLD, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03132662
- Testing
- Omega-3, Very Low Calorie Diet
- Volunteers
- 60 people
- Sponsor
- McMaster University
Fatty Liver, Fatty Liver, Alcoholic
Fatty Liver Disease Collaborative Research in China
A multi-center, prospective cohort study on the natural history of fatty liver disease in China
- Conditions
- Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease
- Trial name
- FLDCR (NCT02391168)
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Fatty Liver and Alcoholic Liver Disease Study Group, China
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Non-Alcoholic Fatty Liver Disease
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
The purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids will decrease the amount of fat in liver.
- Trial name
- NCT00230113
- Testing
- Fish oil, Safflower oil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.